Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare the predictive ability of ALBI and PALBI grades with CTP and MELD scores.
To investigate the efficacy of ALBI and PALBI grades for predicting the prognosis of HCC and overall survival among different modalities of treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ALBI | Diagnostic Test | Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades for prognosis of HCC |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score | We will compare the ability of ALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores | 2 years |
| Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score | We will compare the ability of PALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival among HCC patients according to treatment modality as assessed by the albumin-bilirubin (ALBI) score | We will compare the ability of ALBI score to predict overall survival among HCC patients stratified according to treatment modality (Surgical resection, local ablation, trans-arterial chemoembolization, sorafenib and best supportive care) | 2 years |
Not provided
Inclusion Criteria:
• The diagnosis of HCC will be based on the presence of an arterial hypervascular focal lesion > 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (CT), or dynamic magnetic resonance imaging (MRI)) or two imaging modalities demonstrating the before mentioned feature for lesions < 2 cm with or without elevated serum alpha-fetoprotein (AFP) levels.
Exclusion Criteria:
Not provided
Not provided
This study will include all patients diagnosed with HCC both males and females equal to or above 18 years old, attending the outpatient clinic or admitted at the inpatient section of Tropical Medicine and Gastroenterology Department, Sohag University Hospital
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sohag University | Sohag | 82524 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI) | We will compare the ability of PALBI score to predict overall survival among HCC patients stratified according to treatment modality (Surgical resection, local ablation, trans-arterial chemoembolization, sorafenib and best supportive care) | 2 years |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |